eLife (Nov 2022)

The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression

  • Nehal Gupta,
  • Hanbing Song,
  • Wei Wu,
  • Rovingaile K Ponce,
  • Yone K Lin,
  • Ji Won Kim,
  • Eric J Small,
  • Felix Y Feng,
  • Franklin W Huang,
  • Ross A Okimoto

DOI
https://doi.org/10.7554/eLife.77072
Journal volume & issue
Vol. 11

Abstract

Read online

Human prostate cancer can result from chromosomal rearrangements that lead to aberrant ETS gene expression. The mechanisms that lead to fusion-independent ETS factor upregulation and prostate oncogenesis remain relatively unknown. Here, we show that two neighboring transcription factors, Capicua (CIC) and ETS2 repressor factor (ERF), which are co-deleted in human prostate tumors can drive prostate oncogenesis. Concurrent CIC and ERF loss commonly occur through focal genomic deletions at chromosome 19q13.2. Mechanistically, CIC and ERF co-bind the proximal regulatory element and mutually repress the ETS transcription factor, ETV1. Targeting ETV1 in CIC and ERF-deficient prostate cancer limits tumor growth. Thus, we have uncovered a fusion-independent mode of ETS transcriptional activation defined by concurrent loss of CIC and ERF.

Keywords